Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Sameer Bansilal, Zachary Bloomgarden, Jonathan L. Halperin, Anne S. Hellkamp, Yuliya Lokhnygina, Manesh R. Patel, Richard C. Becker, Günter Breithardt, Werner Hacke, Graeme J. Hankey, Christopher C. Nessel, Daniel E. Singer, Scott D. Berkowitz, Jonathan P. Piccini, Kenneth W. Mahaffey, Keith A.A. Fox
Research output: Contribution to journal › Article › peer-review
138Scopus
citations
Fingerprint
Dive into the research topics of 'Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)'. Together they form a unique fingerprint.